Cargando…

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma

The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific onc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saei, Azad, Eichhorn, Pieter Johan Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721815/ https://www.ncbi.nlm.nih.gov/pubmed/31416288 http://dx.doi.org/10.3390/cancers11081176

Ejemplares similares

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2018)

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
por: Wright, Sarah Christine Elisabeth, et al.
Publicado: (2021)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
por: Proietti, Ilaria, et al.
Publicado: (2020)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
por: Savoia, Paola, et al.
Publicado: (2020)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
por: Luebker, Stephen A., et al.
Publicado: (2019)

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
por: Spagnolo, Francesco, et al.
Publicado: (2015)

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
por: Saei, Azad, et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
por: Baenke, Franziska, et al.
Publicado: (2015)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
por: Koroknai, Viktoria, et al.
Publicado: (2020)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
por: Smalley, Inna, et al.
Publicado: (2019)

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
por: Kakadia, Sunilkumar, et al.
Publicado: (2018)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
por: Parker, Robert, et al.
Publicado: (2015)

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
por: Vergani, Elisabetta, et al.
Publicado: (2022)

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
por: Tian, Yangzi, et al.
Publicado: (2020)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
por: Crispo, Fabiana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ivt8b75c2g1708cqjnf63aeke7